- Asia
- Automobile
- Bangladesh
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Competition Law
- Constitutional Law
- Consumer Law
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Right Management
- Educational Conferences/ Seminar
- Fashion Law
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Legal Issues
- Licensing
- Media & Entertainment Law
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Patent Act
- Patent Commercialisation
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- TAX
- Technology
- Telecom Law
- Trademark
- Trademark Litigation
- Uncategorized
- USPTO
- Vietnam
All About Section 31 D of Copyright Act, 1957
The 2012 amendment in Copyright Act has introduced various provisions, one of them being section 31 D. This section is concerned with the broadcasting or performance of a literary or musical and sound recording, which has already been published. Clause 1 of Section 31D states: “Any broadcasting organization desirous of communicating to the public by … Continue reading All About Section 31 D of Copyright Act, 1957
Read more »CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
17th December, 2014 - 8:25 am
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments
As reported in TOI, the Indian Government has found very little merit in Cipla’s plea for waiver and cancellation of Patent rights for chronic obstructive pulmonary disease (COPD) drug over which Novartis has exclusive rights. We have reported on Cipla’s plea here. Background: Cipla, previously approached the Department of Industrial Policy and Promotion (DIPP) to … Continue reading CIPLA’s plea for revocation of Novartis Patents for Onbrez may face major set back by the Government
Read more »Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
1st November, 2014 - 5:27 pm
Categories:
India
IP Litigation
IP Practice in India
News & Updates
Patent Litigation
Patents
pharma
Pharma/Biotech Patent Litigations
0 Comments
It has been recently reported in Economic times that Cipla has filed representation with the government (Department of Industrial Policy & Promotion) seeking revocation of five patents of Novartis on indacaterol, a respiratory drug for the treatment of chronic obstructive pulmonary disease (COPD) and marketed as Onbrez by Novartis. The central government, under section 66 … Continue reading Cipla Files Representation with Govt. Seeking Revocation of Novartis’ Patents
Read more »